GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » enGene Holdings Inc (NAS:ENGN) » Definitions » 3-Year Share Buyback Ratio

ENGN (enGene Holdings) 3-Year Share Buyback Ratio : -30.00% (As of Apr. 2025)


View and export this data going back to 2023. Start your Free Trial

What is enGene Holdings 3-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. enGene Holdings's current 3-Year Share Buyback Ratio was -30.00%.

The historical rank and industry rank for enGene Holdings's 3-Year Share Buyback Ratio or its related term are showing as below:

ENGN' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -30   Med: -30   Max: -30
Current: -30

During the past 5 years, enGene Holdings's highest 3-Year Share Buyback Ratio was -30.00%. The lowest was -30.00%. And the median was -30.00%.

ENGN's 3-Year Share Buyback Ratio is ranked worse than
78.4% of 1250 companies
in the Biotechnology industry
Industry Median: -9.75 vs ENGN: -30.00

Competitive Comparison of enGene Holdings's 3-Year Share Buyback Ratio

For the Biotechnology subindustry, enGene Holdings's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


enGene Holdings's 3-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, enGene Holdings's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where enGene Holdings's 3-Year Share Buyback Ratio falls into.


;
;

enGene Holdings 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.


enGene Holdings (NAS:ENGN) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


enGene Holdings 3-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of enGene Holdings's 3-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


enGene Holdings Business Description

Traded in Other Exchanges
N/A
Address
4868 Rue Levy, Suite 220, Saint-Laurent, QC, CAN, H4R 2P1
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Executives
Forbion Growth Opportunities Fund I Cooperatief U.a. 10 percent owner GOOIMEER 235, 1411 DC, NAARDEN P7 00000
Fonds De Solidarite Des Travailleurs Du Quebec 10 percent owner 545 CREMAZIE BLVD. EAST, SUITE 200, MONTREAL A8 H2M 2W4
Richard M Glickman director C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Jason David Hanson director, officer: Chief Executive Officer 8125 NORTH HAYDEN ROAD, SCOTTSDALE AZ 85258-2463
Lumira Capital Investment Management Inc. 10 percent owner 141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5
Richard Paul Bryce officer: Chief Medical Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Gerald A Brunk director C/O MDS CAPITAL, 245 FIRST ST., STE 1800, CAMBRIDGE MA 02142
Jasper Bos director BOUNDARY HALL, PO BOX 1093, CRICKET SQUARE, GRAND CAYMAN E9 KY1-1102
Grassin Alexandre Jean-rene Erwan officer: Int. Chief Financial Officer 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Anthony Tzeyew Cheung officer: Chief Technology Officer 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Alexander Julian Nichols officer: Pres. & Chief Operating Ofc. 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
James Crowley Sullivan officer: Chief Scientific Officer 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Forbion Growth Sponsor Feac I B.v. 10 percent owner GOOIMEER 2 35,, NAARDEN P7 1411DC
Forbion Growth Management B.v. 10 percent owner C/O FORBION EUROPEAN ACQUISITION CORP., 4001 KENNETT PIKE, SUITE 302, WILMINGTON DE 19807